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Abstract
Background: Cluster headache is classified as a primary headache by definition not caused by an underlying pathology.
However, symptomatic cases of otherwise typical cluster headache have been reported.
Case presentation: A 47-year-old male suffered from primary chronic cluster headache (CCH, ICHD-3 beta criteria
fulfilled) since the age of 35 years. A magnetic resonance imaging (MRI) study of the brain in 2006 came back
normal. He tried several prophylactic treatments but was never longer than 1 month without attacks. He was under
chronic treatment with verapamil with only a limited effect on the attack frequency. Subcutaneous sumatriptan 6 mg
injections were very effective in aborting attacks. By February 2014 the patient developed a continuous interictal pain
ipsilateral to the right-sided cluster headache attacks. An indomethacin test (up to 225 mg/day orally) was negative.
Because of the change in headache pattern we performed a new brain MRI, which showed a cystic structure in the
pituitary gland. The differential diagnosis was between a Rathke cleft cyst and a cystic adenoma. Pituitary function tests
showed an elevated serum prolactin level. A dopamine agonist (cabergoline) was started and the headache subsided
completely. Potential pathophysiological mechanisms of pituitary tumor-associated headache are discussed.
Conclusion: Neuroimaging should be considered in all patients with CCH, especially those with an atypical presentation
or evolution. Response to acute treatment does not exclude a secondary form of cluster headache. There may be shared
pathophysiological mechanisms of primary and secondary cluster headache.
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Background
Cluster headache (CH) is classified as a primary headache
by definition not caused by an underlying pathology.
However, numerous symptomatic cases of otherwise typ-
ical CH have been reported. We want to report a case of a
man with typical chronic cluster headache (CCH) and a
pituitary lesion only found on repeat MRI. Potential
mechanisms underlying this association are discussed. We
hope this will be useful to other clinicians taking care of
patients suffering from this devastating condition [1].
Case presentation
A 47 year-old man was diagnosed with CH at the age of
35. A 1,5 Tesla MRI of the brain in another hospital was
reportedly normal. The patient came under our care in
2011. The headache attacks and pattern were compatible
with a primary CCH diagnosis according to the criteria of
the International Headache Society (ICHD-3 beta, 3.1.2)
[2]. The patient described attacks of strictly right-sided
orbitotemporal headache associated with ipsilateral tear-
ing and nasal congestion. The attacks lasted from 20 to
60 min, with a frequency up to 4 attacks per day, often
including one attack at night. The most consistent trigger
was alcohol intake. Subcutaneous sumatriptan 6 mg in-
jections were very effective in aborting attacks, inhaled
high-flow oxygen was not. Despite different prophylac-
tic treatments (verapamil up to 480 mg/day, lithium up
to 800 mg/day, topiramate up to 400 mg/day) the pa-
tient was never longer than 1 month without attacks.
By February 2014 the patient developed a continuous
interictal pain ipsilateral to the right-sided CH attacks.
At that point in time he was under chronic treatment
with verapamil (maximal tolerated dose of 560 mg/day)
for 6 months with only a mild effect on attack frequency.
An indomethacin test (up to 225 mg/day orally) was nega-
tive. Because of the change in headache pattern we decided
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to perform a new brain MRI, which showed a cystic
structure in the pituitary gland (Fig. 1). The differential
diagnosis was between a Rathke’s cleft cyst or a cystic
adenoma. Pituitary function tests (PFTs) came back
normal, except for an elevated prolactin level (68.4 μg/
L, normal values 4–17 μg/L) and a low free testosterone
level (4.44 ng/dL, normal values 6–25 ng/dL). This
could be due to verapamil-induced hyperprolactinemia
or a prolactinoma. There was no galactorrhea, gynaeco-
mastia, or erectile dysfunction (but he acknowledged a
low libido), and visual fields were full. The patient was
not willing to stop the treatment with verapamil as he
feared an increase in cluster attack frequency. The pa-
tient was referred to an endocrinologist, who started
carbergoline, a dopamine agonist, at a dose of 0,25 mg
twice a week. Within a few weeks after the start of the
cabergoline treatment the CH attacks subsided com-
pletely and verapamil could be successfully stopped.
The serum prolactin and testosterone levels normal-
ized. A repeat MRI in October 2015 demonstrated a
30 % reduction in size of the cystic pituitary lesion. At
present the patient has been on carbergoline treatment
for 1,5 year and the cluster headaches haven’t returned
ever since and prolactin levels remained within normal
range. Interestingly, the patient reports to experience a
new type of unilateral frontotemporal headache attacks
since about 6 months. These attacks are milder and
shortlasting (seconds), and the pain is rather stabbing.
There are no associated cranial autonomic symptoms.
These attacks are not disabling and the patient does
not need treatment for them. We have labeled these
probable short-lasting unilateral neuralgiform head-
ache attacks (ICHDI-3 beta, 3.5.3) within the given
context.
Discussion
Secondary cluster headache
The lesion in the pituitary and the headaches could just
be a co-occurrence. However the temporal relationship
between the initiation of carbergoline treatment and dis-
appearance of the cluster headache attacks suggests a
potential causal relationship with the pituitary lesion and
(worsening of ) the headache condition. This adds to nu-
merous recent reports of secondary cluster-like head-
ache (CLH). By definition before concluding to a
primary headache potential causative disorders should
be excluded to rule out a secondary CLH. Edvardsson
reviewed 63 cases of symptomatic CH associated with
vascular problems (44 %), tumours (40 %) or inflamma-
tion/infection (11 %) [3]. Of the 63 cases 48 % fulfilled
the criteria for CH. A larger cohort of 156 cases of CLH
showed a similar distribution of causative disorders [4].
On first observation, 50 % of CLH perfectly mimicked
CH at presentation [5]. Furthermore, the response to
typical CH medications does not exclude a secondary
form. Red flags could be older age at onset, abnormal-
duration/frequency/localization, change in clinical char-
acteristics or response to treatment, or an abnormal
neurological/general examination [4, 5]. These findings
suggest that neuroimaging should be considered in all
patients with CH, even typical cases. The ICHDIII beta
criteria for secondary headache disorders require evi-
dence of causation, which includes that ‘headache has
significantly worsened in parallel with worsening of the
presumed causative disorder’ and ‘headache has signifi-
cantly improved (or disappeared) in parallel with im-
provement of the presumed causative disorder’. In our
patient neuro-imaging was done early in his headache
trajectory and results came back normal. However, in
Fig. 1 MRI of the pituitary gland. T1 contrast-enhanced images. Left image: sagittal view. Right image: coronal view. White arrow indicates cystic
structure in the pituitary
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retrospect we noted that the spatial resolution of the ini-
tial MRI of the brain at the level of the pituitary gland
was too low to exclude that the cystic structure (Fig. 1)
was already present. Even though interictal headache in
cluster headache is not an uncommon phenomenon [6],
it was the change in headache history in our patient that
sparked repeat neuro-imaging.
Pathophysiology
The pathophysiology of secondary CLH associated with
pituitary disorders is not well-known. A few hypotheses
are considered and summarized in Fig. 2. The long-held
theory that CH was the related to a cerebrovascular
problem radically changed in the late nineties with CH
attacks being recoined as neurovascular in origin and
with an important role for the hypothalamic-pituitary
axis in the generation of these attacks. Functional im-
aging studies (fMRI, PET), neuro-endocrine changes
(melatonin, cortisol, testosterone, …) and the circadian/
circannual rhythmicity all point to an alteration in the
hypothalamus [7–10]. Also lithium, which is one of the
known preventative treatment options for CH, is hetero-
geneously distributed in the brain and seems to accumu-
late in the hypothalamus and pituitary gland [11, 12].
The pain during cluster headache attacks is attributed to
activation of the trigeminovascular system and cranial
autonomic symptoms are generated via the trigeminal-
autonomic reflex [13–15].
A structural lesion in the hypothalamic-pituitary axis
could lead to an autonomic imbalance resulting in an
attack-wise presentation of complaints. Others have sug-
gested that the headache due to a lesion in the pituitary
is a result of dura mater stretch or invasion of the cav-
ernous sinus. Indeed, the cavernous sinus lateral to the
sella turcica contains the ophthalmic and maxillary
branches of the trigeminal nerve as well as the internal
carotid artery, which are structures that can generate
pain. However, in a systematic study of headache in
patients with pituitary tumors, no correlation between
pituitary volume and headache or between headache and
cavernous sinus invasion was found [16]. Pituitary
tumor-associated headache may have a biochemical-
neuroendocrine basis rather than a structural one [16].
Finally, there is some evidence for the role of “nocicep-
tive peptides” [17]. The presence of calcitonin gene
related peptide (CGRP) or substance P in pituitary tu-
mors does not seem to be associated with headache [15].
Other candidate peptides are vasoactive intestinal pep-
tide (VIP), pituitary adenylate cyclase-activating protein
and neuropeptide Y.
Pituitary function tests, prolactin and dopamine agonist
A few additional questions are provoked by this case. Is
the raised serum prolactin level due to the lesion in the
pituitary or induced by the high dose of verapamil? Is
the effect of cabergoline proving that the lesion is a
prolactinoma and the cause of the headache? Is the
positive effect of carbergoline due to the normalization
of serum prolactin? Is there a need for screening with
PFT’s in CH?
There are physiologic, pituitary and systemic (including
medications, such as verapamil) causes of hyperprolacti-
nemia [18]. Pituitary causes include prolactin-secreting pi-
tuitary adenoma or disconnection hyperprolactinemia due
to a lesion that compresses the pituitary stalk [18]. L-type
calcium channel blockers, such as verapamil, are known
to cause a doubling of serum prolactin levels [19]. Since
the patient was reluctant to stop verapamil because of fear
increased CH attack frequency, we could not distinguish
between both mechanisms prior to initiation of cabergo-
line treatment. Cabergoline is a long acting D2 dopamine
receptor agonist that inhibits prolactin secretion. There
Fig. 2 Potential pathophysiological links with the pituitary gland in cluster headache. (+) arguments pro (-) arguments con. “Size is not everything” is a
reference to an article of Levy et al. [16]. V1 is the ophthalmic branch of the trigeminal nerve. HPA = hypothalamic-pituitary axis. The figure is further
explained in the text under the heading “pathophysiology”
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are reported cases of microprolactinomas manifesting with
headache that resolved after administration of a dopamine
agonist [20, 21], but there are also reports stating the op-
posite [22]. The effect of cabergoline on headache doesn’t
seem to be associated with the normalization of serum
prolactin [20]. Potential mechanisms include alterations to
the pain-modulating dopaminergic system and carbergo-
line, an ergot derivative, also possesses significant affinity
for certain subtypes of serotonergic and adrenergic recep-
tors. A normal MRI of the brain does not exclude a micro-
adenoma [23], and PFT’s should therefore be considered in
(refractory) patients with CCH or other (TAC).
Conclusion
Neuroimaging should be considered in all patients with
CCH, especially those with an atypical presentation or
evolution. When performing brain imaging it seems im-
portant to pay extra attention to the pituitary/parasellar
region. Response to acute treatment does not exclude a
secondary form of CH. PFTs should be considered in pa-
tients suffering from (refractory) CCH or other TACs.
Cabergoline may have a dramatic effect on CH in pa-
tients with coexistent hyperprolactinemia.
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